Benitec Biopharma Inc. Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Benitec Biopharma Inc. (BNTC) reported Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $9.47 million for the 12-month period ending 2021-06-30, per its 10-K filed 2021-09-20.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2021-09-20
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-09-30 was -$2.53M, a 306.61% decline year-over-year.
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-09-30 was $1.23M.
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $9.47M.
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$5.86M, a 233.46% decline from fiscal 2019.
- Benitec Biopharma Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $4.39M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|
| 2021-06-30 | $9.47M 10-K · filed 2021-09-20 | |
| 2020-09-30 | -$2.53M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$5.86M 10-K · filed 2021-09-20 | |
| 2019-09-30 | $1.23M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $4.39M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |